Chronic liver disease mediated by activation of hepatic stellate cells (HSCs) and Kupffer cells (KCs) leads to liver fibrosis. Here, we aimed to investigate the molecular mechanism and define the cell type involved in mediating the sphingosine kinase (SphK)1-dependent effect on liver fibrosis. The levels of expression and activity of SphK1 were significantly increased in fibrotic livers compared with the normal livers in human. SphK1 was coexpressed with a range of HSC/KC markers including desmin, a-smooth muscle actin (a-SMA) and F4/80 in fibrotic liver. Deficiency of SphK1 (SphK1 (1) Advance fibrosis is characterized by accumulation of activated a-smooth muscle actin (a-SMA)-positive periportal and perisinusoidal myofibroblasts that lead to scar formation composed of collagens.
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) resulted in a marked amelioration of hepatic injury, including transaminase activities, histology, collagen deposition, a-SMA and inflammation, in CCl 4 or bile duct ligation (BDL)-induced mice. Likewise, treatment with a specific inhibitor of SphK1, 5C, also significantly prevented liver injury and fibrosis in mice induced by CCl 4 or BDL. In cellular levels, inhibition of SphK1 significantly blocked the activation and migration of HSCs and KCs. Moreover, SphK1 knockout in KCs reduced the secretion of CCL2, and SphK1 knockout in HSCs reduced C-C motif chemokine receptor 2 ([CCR2] CCL2 receptor) expression in HSCs. CCL2 in SphK1 2/2 mice was lower whereas microRNA-19b-3p in SphK1 2/2 mice was higher compared with wild-type (WT) mice. Furthermore, microRNA-19b-3p downregulated CCR2 in HSCs. The functional effect of SphK1 in HSCs on liver fibrosis was further strengthened by the results of animal experiments using a bone marrow transplantation (BMT) method. Conclusion: SphK1 has distinct roles in the activation of KCs and HSCs in liver fibrosis. Mechanistically, SphK1 in KCs mediates CCL2 secretion, and SphK1 in HSCs upregulates CCR2 by downregulation of miR-19b-3p. (HEPATOLOGY H epatic fibrosis is characterized by excess accumulation of extracellular matrix that follows chronic liver injury. (1) Advance fibrosis is characterized by accumulation of activated a-smooth muscle actin (a-SMA)-positive periportal and perisinusoidal myofibroblasts that lead to scar formation composed of collagens. (1) Ongoing inflammation often results in massive fibrosis and finally cirrhosis, which is accompanied by architectural distortion of the hepatic vasculature and sets the stage for hepatic Abbreviations: ALT, alanine aminotransferase; AST, asparate aminotransferase; a-SMA, a-smooth muscle actin; BDL, bile duct ligation; BM, bone marrow; BMSCs, bone marrow-derived mesenchymal stem cells; BMT, bone marrow transplantation; CCL2, C-C motif chemokine ligand 2; CCR2, C-C motif chemokine receptor 2; Col1a1, collagen type I alpha 1; ECM, extracellular matrix; HSCs, hepatic stellate cells; KCs, kupffer cells; NPs, nanoparticles; SphK, sphingosine kinase; S1P, sphingosine-1-phosphate; TGF-bR2, TGF-b receptor 2; TIMP-1, TIMP metallopeptidase inhibitor 1; TGF-b1, transforming growth factor-b; WT, wild-type.
decompensation, primary liver cancer, and death. (2) Upon liver injury, hepatic stellate cells (HSCs), the major collagen-synthesizing cells in the liver, become activated and transdifferentiate into myofibroblast-like cells that proliferate faster and display enhanced chemotaxis, survival and collagen production.
(1) HSCs also play an important role in linking hepatic inflammation to fibrogenesis. (3) HSC activation is driven by multiple mediators, such as chemokines, reactive oxygen species, growth factor, matrix stiffness, matricellular proteins and damage-associated molecular patters, which are also secreted by neighboring cells and signals to drive scarring by HSCs in an autocrine and/or paracrine fashion. (4, 5) However, a limitation of the current anti-fibrotic therapy is that medicinal candidates cannot specifically target HSCs. Therefore, understanding the molecular mechanism of fibrogenesis is important for the development of effective antifibrotic therapies.
Macrophages are key drivers of fibrogenesis and found in close proximity with collagen-producing myofibroblasts. A crucial step in the initiation of liver fibrosis is a strong inflammatory response. Liver resident macrophages (Kupffer cells [KCs] ) become activated and release proinflammatory and profibrotic mediators that activate quiescent HSCs into myofibroblasts producing a-SMA. (6, 7) Several studies have emphasized the crucial role of infiltrating monocytes/ macrophages for the progression of liver inflammation and fibrosis in experimental mouse models (8, 9) and in patients with liver cirrhosis. (10) KCs are greatly augmented by an overwhelming number of infiltrating monocytes upon acute or chronic liver injury. Chemokines have been identified as central regulators of liver fibrosis. In conditions of liver damage, C-C motif chemokine receptor (CCR)2 and its ligand, monocyte chemotactic protein-1/C-C motif chemokine ligand 2 (monocyte chemotactic protein-1/CCL2), promote monocyte subset infiltration into the liver. (9, 11, 12) The expression of CCL2 is associated with infiltration of monocytes. (13) The functional relevance of the CCL2-CCR2 pathway has been extensively confirmed in various experimental models of liver fibrosis using genetic deletion of CCL2, CCR2 or pharmacological inhibition of CCL2, resulting in attenuation of liver fibrosis in mice. (9, 11, 14, 15) Sphingosine-1-phosphate (S1P) is a pleiotropic lipid mediator that acts either on G protein-couple S1P receptors on the cell surface or via intracellular target sites. S1P is converted from sphingosine by two isoforms of sphingosine kinases (SphK1 and SphK2). (16) Among the chemokines and inflammatory mediators known to exert potent cellular chemotactic effects, the S1P has been recognized as an important regulator of fibrosis in lung, kidney, heart and skin. (17) (18) (19) (20) (21) Recent reports showed that a SphK1/S1P/S1PR signaling axis was involved in liver injury and fibrosis. (22) (23) (24) (25) SphK inhibitor can reduce angiogenesis in fibrotic mice (24) and block the differentiation from bone marrow-derived mesenchymal stem cells (BMSCs) to myofibroblasts during liver injury, (26) suggesting that targeting SphK might be a therapy in the treatment of liver fibrosis. However, the protective effects of SphK1 knockout in vivo and cell-typespecific roles of the SphK1 in the pathogenesis of liver fibrosis have not been defined yet.
Therefore, the current study aimed to characterize the cell-type-specific contribution of SphK1 activation during liver fibrosis. We address the profibrotic roles of SphK1 by combination of SphK1 knockout mice and bone marrow transplantations (BMTs). The current study showed that knockout of SphK1 in mice or inhibition of SphK1 activity attenuates liver fibrosis in mice. We demonstrate that SphK1 in HSCs, plays a crucial role during liver fibrosis. Together, these results represent direct experimental evidence that SphK1 is a therapeutic target for liver fibrosis.
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Materials and Methods
ANIMALS
Specific pathogen-free C57BL/6 mice were obtained from the Medical Laboratory Animal Center (Guangzhou, China). SphK1 knockout (SphK1 2/2 ) mice were C57BL/6 background and donated by Richard Proia of National Institute of Health. PCR screening of SphK1 was performed using the following primers: SphK1-1:
0 ; All mice received human care and animal experiments were approved by the University Committee on Use and Care of Animals of the Guangdong Pharmaceutical University, Guangzhou, China.
miRNA MICROARRAY
Total RNA including miRNA was isolated with TRIZOL Reagent (Invitrogen, Massachusetts, USA) from liver tissues treated with CCl 4 or corn-oil (vehicle control) for 6 weeks, following the manufacturer's instructions. RNA quantity and quality were determined using a nanodrop (Thermo Scientific, Massachusetts, USA) and Bioanalyzer (Agilent Inc., California, USA). Total RNA (100 ng) was labelled with desalted Cy3 using an miRNA Complete Labeling and Hyb kit (Agilent) and then hybridized to an Agilent miRNA expression microarray in accordance with the manufacturer's instructions. A Sureprint G3 Mouse miRNA Microarray (Release 19.0, 8 x 60K; Agilent). For microarray analysis, raw data were first filtered by a flag signal detected in all samples. Filtered raw data were processed using the Limma Bioconductor package (http://www.bioconductor.org/) in the R statistical environment (http://www.r-project.org/). After quantile normalization of data, miRNAs with twofold or greater differential expression were identified, with P-values of < 0.05 being considered statistically significant.
BONE MARROW TRANSPLANTATION
Bone marrow transplantation (BMT) was performed as described previously. Briefly, mice were macrophage depleted by injection of liposomal clodronate (10 ll/g, Clodrosome, TN,USA), followed by lethal irradiation with 10.8 Gy and intravenous injection of 1 x 10 7 bone marrow (BM) cells from donor mice. Successful BM transplantation was confirmed by the absence of SphK1-positive macrophages in the liver (Supporting Fig. S4 ).
CHEMOKINE ARRAY
Hepatic chemokine secretion profile was screened using a mouse chemokine array kit (RayBiotech, Georgia, USA) following manufacturer's instructions. The array consists of 25 different mouse chemokine antibodies spotted in duplicate onto membranes. Array membranes were incubated for 1 hour in blocking buffer and then incubated overnight with liver protein lysates. The membranes were washed and incubated with streptavidin-horseradish peroxidase and Chemi Reagent Mix. The intensity of each chemokine spot was determined by Image J software and represented as relative expression compared with control.
LUCIFERASE REPORTER ASSAY
Plasmids of GP-miRGLO (Genepharma, Shanghai, China) containing either the WT or mutated CCR2 mRNA 3 0 UTR were cotransfected with miR19b-3p mimic or negative control in primary HSCs. After transfection for 48 hours, the cells were lysed for luciferase activity with a Dual-LuciferaseV R Reporter Assay System (Promega, Madison, WI, USA), and firefly luciferase activity was normalized to Renilla luciferase activity.
ADDITIONAL MATERIALS AND METHODS
A detailed description of methodologies used in this study can be found in the Supporting Materials and Methods.
STATISTICAL ANALYSIS
Values were expressed as mean 6 standard deviations. Statistical differences between two groups were analyzed by the unpaired Student t test with a twotailed distribution. Differences between multiple groups of data were analyzed by one-way ANOVA with Bonferroni correction (Graph Pad Prism 6.0, San Diego, CA, USA). A P value <0.05 was considered statistically significant.
Results
SPHK1 SIGNALING IS ACTIVATED IN HUMAN AND RODENT LIVER FIBROSIS
We initially examined SphK1 levels in human liver fibrotic tissue in HBV-induced cirrhosis and primary biliary cirrhosis. SphK1 mRNA expression increased significantly in liver fibrosis biopsies (Fig. 1) . Immunohistochemical analyses revealed that hepatic SphK1 expression was higher in patients with cirrhosis than healthy control (Fig. 1A) . The fibrotic areas were represented by sirius red staining and activated HSCs were represented by a-SMA positive staining. Furthermore, SphK1 expression was accumulated in hepatic collagen area (Fig. 1A) . Moreover, a-SMA mRNA levels were higher in cirrhotic livers than in healthy livers. As expected, the mRNA levels of SphK1 were elevated in cirrhotic livers (and positively correlated with mRNA levels of a-SMA Fig. 1B) . Consistently, the protein expression and activity of SphK1 was also markedly increased in cirrhotic livers (Fig. 1C,D) . We also observed elevation of SphK1 expression and activity in a mouse model of liver fibrosis induced by CCl 4 (Fig. 1E,F) . Interestingly, CCl 4 -injured mouse liver displayed SphK1 staining in cells with a myofibroblast-like morphology in fibrotic tissue (Fig.  1E ). These data indicate that SphK1 is upregulated in cirrhotic livers, raising the hypothesis that the activation of SphK1 signaling plays a role in the activation of HSCs and the progression of liver fibrosis.
To define the cellular distribution of SphK1, we performed immunofluorescence double staining of SphK1 with desmin (a marker for HSCs), a-SMA (a marker for activated HSCs), F4/80 (a marker for KCs), or albumin (a marker for hepatocytes), we found that SphK1 was expressed in HSCs and KCs, but not in hepatocytes. Furthermore, SphK1 was dramatically upregulated and primarily expressed in HSCs after chronic liver injury (Supporting Fig. S1 ).
DEFICIENCY OF SphK1 PROTECTS AGAINST LIVER FIBROSIS IN MICE
On the basis of the increase in SphK1 expression in fibrotic liver, we then examined the role of SphK1 signaling in hepatic fibrosis in SphK1 knockout (SphK1 2/2 ) mice subjected to CCl 4 or bile duct ligation (BDL). Mice were repetitively exposed to CCl 4 for 6 weeks. Hematoxylin and eosin (H&E) and sirius red staining assays revealed that SphK1 deficiency inhibited CCl 4 -induced liver injury and fibrosis as compared with controls. Consistently, deficiency of SphK1 notably attenuated upregulation of a-SMA and collagen type 1 (Col1a1), the most abundant extracellular matrix (ECM) protein in the fibrotic liver. Similarly, the immunostaining of CD68, a wellestablished marker of activated macrophage marker, was also decreased in SphK1 2/2 mouse liver ( Fig.  2A) . The hepatic mRNA levels of fibrogenic genes (a-SMA, Col1a1, TGF-b1, TIMP-1 and PDGF) were reduced in CCl 4 -injured SphK1 2/2 mice (Fig.  2B) . Consistently, the hepatic mRNA levels of inflammatory genes (F4/80, TNF-a and IL-1b) were also decreased in CCl 4 -injured SphK1 2/2 mice (Fig.  2C) . The low level of fibrosis observed in SphK1-/-mice may have been a result of attenuation of the injury process. As expected, the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly diminished in SphK1 2/2 mice, indicative of improvement of liver damage (Fig. 2D ). In addition, immunoblotting results showed that the expression of a-SMA and collagen I was reduced in fibrotic liver from SphK1 2/2 mice than WT mice (Fig. 2E) .
To further analyze the role of SphK1 in liver fibrosis, we employed the BDL mouse model of liver fibrosis, another well-established model. SphK1 deficiency attenuated the development of liver fibrosis in BDLoperated mice for 15 days, as evidenced by histopathological improvement and the changes in Sirius Red staining. Repression of a-SMA and CD68 staining was observed in BDL-operated SphK1 2/2 mice compared with WT mice (Fig. 3A) . The hepatic mRNA levels of fibrotic and inflammatory factors were also suppressed in SphK1 2/2 mice operated by BDL for 15 days (Fig. 3B,C) , correlated with decreased serum levels of ALT and AST (vs WT mice, [ Fig. 3D]) To validate the biological impact of SphK1 deficiency, we also used mouse models of acute hepatitis induced by a single injection of CCl 4 or BDL for 5 days, respectively. Liver inflammatory cell infiltration and hepatocyte necrosis were increased in WT mice subjected by CCl 4 or BDL. In concordance, the expression of SphK1 was increased in damaged liver (Supporting Fig. S2A) . Consistently, the expression of a-SMA and CD68 was diminished in SphK1 2/2 mice operated by BDL for 5 days (Supporting Fig. S2B ). The qRT-PCR assays for fibrogenic and inflammatory factors confirmed that SphK1 deficiency inhibited fibrogenic and inflammatory gene induction (Supporting Fig. S2C,D) . Additionally, liver function was improved in SphK1 2/2 mice (Supporting Fig. S2E ), suggesting that SphK1 deficiency also has an inhibitory effect on the early pathologic event leading to the liver injury and fibrosis. Taken together, all of these results demonstrate that SphK1 mediates the activation of HSCs and KCs, contributing to the initiation and progression of liver fibrosis.
SphK1 SIGNALING IS REQUIRED FOR HSC ACTIVATION
We hypothesized that the increased SphK1 may regulate HSC activation. Next, we used two methods to inhibit SphK1 signaling: blockage of SphK1 using a specific inhibitor of SphK1 (5C) and knockdown of SphK1 by siRNA. In the current study, LX-2 (a human HSC line with key features of activated HSCs despite limitations due to immortalization) was treated with SphK1 siRNA or 5C. qRT-PCR analysis demonstrated that SphK1 siRNA or 5C significantly reduced the mRNA levels of profibrogeic genes (a-SMA, Col1a1, TGF-b1, TIMP-1 and PDGF) in LX-2 cells (Fig. 4A) , with almost 90% downregulation of SphK1 mRNA by SphK1 silencing (Fig. 4B) . We also found that SphK1 activity was significantly inhibited by 5C or SphK1 siRNA (Fig. 4C) . Consistently, SphK1 siRNA or 5C remarkably downregulated a-SMA in LX-2 cells (Fig. 4D) . In contrast, overexpression of SphK1 in LX-2 cells transfected with SphK1 plasmid further enhance a-SMA expression (Fig. 4E) . These results suggested that SphK1 promotes liver fibrosis involved in the regulation of HSC activation. 
SphK1 DEFICIENCY MAINLY ATTENUATES CHEMOKINE CCL2 SECRETION IN FIBROTIC MOUSE LIVER AND KCS
Inflammatory chemokines known to be critical for the pathogenesis of liver fibrosis. To determine the change of chemokine expression in liver fibrosis, liver tissue lysates from control or fibrotic mice induced by CCl 4 were examined using the chemokine array that contains 25 different chemokine antibodies. We found three chemokines (CCL1, CCL2 and CXCL12) were increased in WT mice, while they were decreased in SphK1 2/2 mice. Especially, CCL2 is one of the most elevated chemokines and dramatically downregulated by SphK1 deficiency (Fig. 5A) . Repression of CCL2 gene expression by SphK1 deficiency was further verified by the results of qRT-PCR assays in mice induced by CCl 4 or BDL (Fig. 5B) . Liver injury triggers KC activation, leading to inflammatory cytokine and chemokine release. (27) Next, we determined the role of SphK1 in CCL2 secretion in KCs. qRT-PCR assay shown that the CCL2 mRNA was significantly reduced in SphK1-deficient KCs compared with WT KCs (Fig. 5C ), suggesting that SphK1 is required for CCL2 production in KCs.
SphK1 MEDIATES CCR2 UPREGULATION AND ACTIVATION IN HSCS INDUCED BY CCL2
CCL2 was found to promote migration and positioning of HSCs. (28) In addition, CCR2 promotes HSC chemotaxis and the development of hepatic fibrosis. (11) To define the effects of SphK1 on the CCL2-CCR2 signaling in HSCs, we performed immunofluorescence double staining of CCL2 with a-SMA (activated HSC marker). In the oil control mice, we found very weak expression of CCR2. However, CCR2 was dramatically augmented in a-SMA 1 HSCs (Fig. 5D) , suggesting that SphK1 regulates CCR2 expression in HSCs. Given that CCL2 acts through its receptor CCR2 in mediating HSC activation, (11, 28) we next examined the role of SphK1 in the activation of HSC induced by CCL2. The expression of CCR2 in primary HSCs isolated from WT mouse liver was significantly induced by CCL2. However, CCR2 was dramatically reduced in SphK1-deficient HSCs (Fig.  5E) . Additionally, qRT-PCR assays for fibrogenic factors (a-SMA, Col1a1 and TGF-b1) verified the inhibitory effect of HSC-specific deletion of SphK1 on fibrogenic gene induction by CCL2 (Fig. 5F ).
MiR-19b-3p, DIRECTLY BINDING TO 3
0 -UTR REGION OF CCR2 mRNA, IS REPRESSED BY CCL 4 
-INDUCED LIVER FIBROSIS AND RESTORED BY SphK1 DEPLETION
To investigate the differences in miRNA expression profiles between fibrotic and normal livers, we performed miRNA microarrays for total RNA extracts isolated from mouse livers treated with CCl 4 or corn Heat map shows the two-way hierarchical clustering of differentially expressed miRNAs. Each row and column represents an miRNA and a condition, respectively. The row Z-score scaling for the expression level of each miRNA was calculated by subtracting the mean expression of the miRNA from its expression value and then dividing by the SD across all the samples. The closer the color is to bright blue, the lower the expression; the closer to bright red, the higher the expression. (B) A list of significantly dysregulated miRNAs in CCl 4 -treated compared with corn-oiltreated livers is shown with the fold change. (C) qRT-PCR was performed to assess expression of the miR-19b-3p in livers from the oil or CCl 4 -treated WT mice, as well as CCl 4 -treated SphK1 2/2 mice at 6 weeks (n 5 8 per group). (D-E) Primary aHSCs were transfected with a scrambled (Scr)-miR (control, white bar), mimic miR-19b-3p (black bar) or anti-miR-19b-3p (gray bar) oligonucleotide for 48 hours, and mRNA levels of miR-19p-3p (D) andCCR2 (E) were analyzed by qRT-PCR assays. (F) Dual-luciferase reporter assays were performed to test the interaction of mmu miR-19b-3p and its targeting sequence in the CCR2 mRNA 3 0 -UTR using GP-miRGLO plasmid constructs containing the predicted targeting sequence (WT-CCR2) and mutated targeting sequence (MUT-CCR2) cloned into the 3 0 -UTR of the reporter gene. The mutated nucleotides were underlined. Plasmids were transfected into primary HSCs together with miR-19b-3p mimic or negative mimic control. The luciferase activity was determined after 48 hours of transfection. Data represent three independent experiments with triplicate measurements. Data are presented as means 6 SD *P<0.05; **P<0.01; ***P<0.001 versus Control. oil for 6 weeks (n 5 6 per group). The miRNAs were considered to have significant differences in expression level when the expression difference showed more than two-fold change between the experimental and control groups at P < 0.05. We found that the expression of 23 miRNAs were altered in fibrotic liver. Thirteen miRNAs were downregulated and the other 10 were upregulated in the CCl 4 group compared with the control. Among these miRNAs downregulated in liver fibrosis, miR-19b-3p had the lowest expression in the livers of CCl 4 -treated WT mice (0.193-fold). This reduced expression of miR-19b-3p was restored in CCl 4 -treated SphK1 2/2 mice (1.934-fold) (Fig.  6A,B) . qRT-PCR assays for miR-19b-3p verified that SphK1 depletion restored the repression of miR-19b-3p by CCl 4 -induced liver fibrosis (Fig. 6C) . To confirm these findings in vivo, we isolated primary HSCs from WT and SphK1 2/2 mice. As primary HSCs are known to be activated during culture, we found that miR-19b-3p was significantly downregulated at day 5 (activated HSCs) compared with day 0 (quiescent HSCs) of culture (Fig. 6D) , these results indicate that these miRNAs were downregulated during HSC activation. Next, primary HSCs were transfected with miR-19b-3p mimic or anti-miR-19b-3p and cultured for 5 days. As expected, miR-19b-3p mRNA was significantly increased in miR-19b-3p mimic-transfected cells, whereas decreased in anti-miR-19b-3p-transfected cells (Fig. 6D) . To identify the relevant target genes of the miR-19b-3p, we conducted bioinformatics analysis using http://www.targetscan.org/, a comprehensive resource of miRNA target predictions. We found that CCR2 was a potential target of miR19b-3p in mice (Supporting Fig. S3A ). We next investigated whether ectopic expression of miR-19b-3p in the aHSCs influenced CCR2 expression and HSC activation. As expected, mRNA levels of CCR2 was significantly downregulated in miR-19b-3p-mimictransfected WT cells, whereas upregulated in antimiR-19b-3p-transfected WT cells. In contrast, CCR2 upregulation by anti-miR-19b-3p was reversed by SphK1 depletion in HSCs (Fig. 6E) . Furthermore, we investigated whether miR-19b-3p interacted with the binding sites at the 3 0 -untranslated region (3 0 -UTR) of CCR2 mRNA using luciferase assay in primary HSCs. We cloned a 3 0 -UTR fragment of CCR2 into pGL3 luciferase reporter vector. These segments included a predicted binding site for miR-19b-3p (Fig. 6F) . Overexpression of miR-19b-3p in HSCs markedly decreased the luciferase activity of 3 0 -UTR in the WT reporter of CCR2. However, the activity was not significantly changed in HSCs transfected with mutant reporter plasmid of CCR2. In addition, there was no effect on the 3 0 -UTR activity following treatment with the miR-negative control (Fig. 6F) . Together, our luciferase reporter assay confirmed that miR-19b-3p directly bound to CCR2 mRNA. Consistently, in primary aHSCs transfected with a miR-19b-3p mimic, expression of the fibrogenic genes encoding for a-SMA, Col1a1 and TIMP-1 was decreased, whereas further increased in aHSCs transfected with anti-miR19b-3p. Interestingly, the upregulation of fibrogenic genes in aHSCs by anti-miR-19b-3p transfection was significantly reversed by SphK1 depletion (Supporting Fig. S3B-E) . Therefore, these results demonstrate that SphK1 deficiency induces miR-19b-3p upregulation, and subsequently attenuates the activation of HSCs by targeting CCR2.
SphK1 ON RESIDENT CELLS, BUT NOT BM-DERIVED CELLS, ARE CRITICAL FOR LIVER FIBROSIS
Because SphK1 is important for liver fibrosis of two animal models and is expressed both in HSCs and KCs (Fig. 7A, Supporting Fig. S1 ), we investigated which cell types are critical in SphK1-mediated liver fibrosis. We generated SphK1-chimeric mice by using a combination of KC depletion (Supporting Fig. S4) , irradiation, and BMT. Liposomal clodronate was injected intraperitoneally to deplete resident KCs after 2 weeks of BMT (Supporting Fig. S4 ). This combination generates complete substitution of KCs and other BM-derived cells, but not of resident hepatic cell populations, including HSCs. Because SphK1 is not expressed in hepatocytes, this protocol reconstitutes KCs, but not HSCs, with BM-derived cells. Thus, we generated two types of SphK1-chimeric mice:
1. WT mice with transplanted SphK1 2/2 BM, which contained SphK1 2/2 KCs and WT HSCs 2. SphK1 2/2 mice with transplanted with WT BM, which contained WT KCs and SphK1 2/2 HSCs.
After a two-month recovery, hepatic fibrosis was induced by way of CCl 4 treatment. After 6 weeks of induction, WT mice transplanted with WT BM (WT BM!WT) had significantly increased collagen deposition as assessed by Sirius red staining. However, SphK1 chimeric mice with SphK1-deficient endogenous liver cells (WT BM!SphK1 2/2 and SphK1
) had reduced fibrosis compared with WT BM!WT mice (Fig. 7A) . In agreement with the results on collagen deposition, WT BM!WT mice showed an increased expression of a-SMA comparable to WT-oil mice, whereas SphK1 2/2 mice containing WT BM (WT BM!SphK1 2/2 ) had decreased a-SMA expression similar to SphK1 2/2 mice transplanted with SphK1
) (Fig. 7A,C,F) . As expected, serum levels of ALT were lower in SphK1 chimeric mice with SphK1-deficient endogenous liver cells (WT BM!SphK1 2/2 and SphK1 2/2 BM!SphK1
) compared with WT mice transplanted with WT BM (WT BM!WT) (Fig. 7B) . However, SphK1 chimeric mice that expressed SphK1 in endogenous liver cells but not BM-derived cells (SphK1 2/2 BM!WT) had a lesser reduced liver fibrosis compared with SphK1 chimeric mice with SphK1-deficient endogenous liver cells (WT BM!SphK1
and SphK1 (Fig. 7A-C,F) . On the contrary, SphK1 2/2 chimeric mice that express SphK1 in BMderived cells but not endogenous liver cells (WT BM!SphK1
) showed the similar reduction of liver fibrosis as mice with complete depletion of SphK1
) (Fig. 7D ). However, WT or SphK1 2/2 mice transplanted with SphK1 2/2 BM showed decreased secretion of CCL2 compared with WT or SphK1 2/2 mice transplanted with WT BM (Fig. 7E) . Taken together, these results suggest that SphK1 expression on recipient-originated cells including HSCs is required for the pathogenesis of liver fibrosis, whereas SphK1 has a lesser role in liver fibrosis in BM-derived cells including macrohage.
INHIBITING SphK1 SIGNALING ALLEVIATES MURINE LIVER FIBROSIS
On the basis of SphK1 deficiency significantly attenuating development of liver fibrosis in mice subjected to CCl 4 or BDL, we finally examined the effect of SphK1 specific inhibitor (5C) on the potential treatment of liver fibrosis in mice induced by CCl 4 or BDL. H&E and Sirius red staining assays revealed that 5C treatment alleviates CCl 4 -induced as compared with vehicle controls. Accordingly, 5C notably reduced a-SMA-staining intensities in the fibrotic livers (Fig. 8A) . The qRT-PCR assay showed that 5C also significantly reduced the mRNA levels of fibrogenic genes (a-SMA, Col1a1, TGF-b1, TIMP-1 and PDGF) (Fig. 8B) . Similarly, an immunoblotting assay verified that repression of a-SMA expression by 5C treatment (Fig. 8C) . In serum biochemistry analyses, ALT was significantly diminished by 5C treatment, indicative of improvement of liver function (Fig. 8D) . Similar results were obtained in BDL-induced liver fibrosis in mice treated with 5C (Supporting Fig. S6 ), suggesting that blockage of SphK1 signaling significantly ameliorates the pathogenesis of liver fibrosis of different etiologies in mice.
Discussion
Earlier studies have demonstrated the relevance of SphK1 signaling activation in chronic liver injury and fibrosis. (20, (24) (25) (26) However, the in vivo role of SphK1 deficiency in the pathogenesis of liver fibrosis has been unclear. In the current study, we first used SphK1 2/2 mice to verify that genetic or pharmacological inactivation of SphK1 attenuated acute and chronic liver injury and fibrosis in mice.
We showed that knockout of SphK1 in mice diminished liver fibrosis with recovery of liver function in CCl 4 -or BDL-induced animal models of liver fibrosis, indicating that deficiency of SphK1 could effectively attenuate the progression of liver fibrosis. In addition, SphK1 knockout prevented the early fibrogenic events initiated by acute liver injury. Consistently, SphK1 specific inhibitor 5C diminished chronic liver injury and fibrosis induced by CCl 4 . Previous studies also showed that SphK inhibitor DMS or SKI attenuated collagen deposition and angiogenesis to protect against liver fibrosis, (24, 25) although DMS or SKI was not specific to SphK1. All of these findings support the conclusion that attenuation of SphK1 signaling prohibits the development and progression of liver fibrosis.
One of the tasks to thoroughly understand the role of SphK1 for liver fibrosis is to characterize and identify their cell-type-specific functions under different conditions. Parenchymal and nonparenchymal liver cells as well as immune infiltrating cells contribute to mechanism of liver injury and fibrosis. Thus, cell-typespecific activation of SphK1 might be relevant to determine the outcome of liver disease. In the present study, our interest focused on defining the relevance of SphK1 activation in different liver cell compartments during liver fibrosis. Investigation of SphK1 expression in the liver of patients with fibrosis or different experimental murine models revealed that the SphK1 expression was upregulated in the fibrotic liver, and positively correlated with the disease progression; this event was particularly associated with the activation of HSCs.
Immunohistochemistry assay showed that SphK1 mainly expressed in non-parenchymal area rather than parenchymal area (hepatocytes) both in human and rodent livers. Furthermore, immuohistofluorescence revealed that both KCs and HSCs expressed SphK1 in normal and fibrotic livers. The recruitment and migration of KCs and HSCs are critical events for developing liver injury and fibrosis. Additionally, most extracellular matrix components are produced by HSCs, and accumulation of these ECM causes liver fibrosis. Cytokines and chemokines stimulate key biological processes in HSCs, such as activation, proliferation, and migration. (29) Moreover, KCs can interact with HSCs, accelerate their activation and promote their fibrogenic response in vitro. (30) Previous studies reported that BMSCs in damaged liver induced by CCl 4 . Furthermore, TGF-b1 induced BMSC differentiation to myofibroblasts accompanied by the upregulation of SphK1. (26) To identify the most relevant target cell of SphK1-mediated profibrotic effects, WT or SphK1 2/2 mice were reconstituted with BM from WT or SphK1 2/2 donors. Our results showed that SphK1 in HSCs majorly contribute to liver fibrosis than SphK1 in KCs. Additionally, increased SphK1 was confirmed in both human HSC LX-2 cells and primary mouse HSCs, and inhibition of SphK1 signaling abrogated HSC activation. These data suggested that SphK1 in HSCs play the major roles in the progression of liver injury and fibrosis.
As firmly established in the literature, disruption of CCR2 signaling impedes liver fibrosis as evidenced by altered the chemotaxis and transdifferentiation of HSCs. (11) Recruitment of immune cells such as KCs and HSCs to the site of injury and inflammation is an important event in regeneration, wound healing, and hepatic fibrosis. (31) Chemokines and chemokine receptors have a central role in the regulation of cell migration and local inflammation. (32) The CCR2 ligand CCL2 can be produced by KCs, which promotes liver fibrosis by recruitment of macrophages that are associated with HSCs. (3, 33) In human liver diseases, increased CCL2 is associated with macrophage recruitment and liver fibrosis progression. (13) In addition, the inactivation of CCL2 attenuates CCl 4 -induced liver injury and fibrosis by inhibiting macrophage recruitment. (33) An important finding of our current study is identification of the paracrine effect of SphK1-mediated CCL2 secretion produced by KC on HSC activation (Fig. 5) . Furthermore, KCs co-culture promoted HSC migration (Supporting Fig. S5 ). Our present study also demonstrated that SphK1 on KCs is required for the secretion of CCL2, however, SphK1 on KCs is not very dispensable for the HSC activation and collagen deposition. Notably, SphK1 on recipientoriginated cells including HSCs is more important than SphK1 on KCs in the regulation of HSC activation and rodent fibrogenesis induced by CCl 4 . Our current study found a regulatory effect of SphK1 on CCL2-CCR2 axis in KCs and HSCs and subsequent promotion of liver fibrogenesis. Moreover, our in vitro results confirmed the in vivo findings and demonstrated that SphK1 is crucial for HSC activation and ECM deposition. Deficiency of SphK1 reduced migration and activation of HSCs associated with downregulation of CCR2 and downstream fibrotic genes.
Recent miRNA microarray analysis performed on quiescent and activated HSCs showed that miR-19b was dramatically downregulated in activated HSCs. Similarly, miR-19b expression was markedly downregulated in fibrotic human livers. miR-19b mimic negatively regulated TGF-b signaling components demonstrated by decreased its direct target gene, TGF-b receptor 2 (TGF-bR2), preventing activated HSC phenotype and progression of rodent liver fibrosis. (34) We analyzed liver tissues of mice treated with CCl 4 for 6 weeks unique mouse miRNA Microarray. Consistently, our results demonstrated that expression of miR-19b-3p declined in fibrotic livers of mouse models with hepatic injury and also in activated HSCs. In addition, miR-19b-3p mimic also downregulated TGF-bR2 in activated HSCs (Supporting Fig. S3D ). In particular, we found evidence that expression of miR-19b-3p was downregulated by SphK1, and reduced miR-19b-3p directly upregulated CCR2 by binding the 3 0 -UTR region of CCR2 mRNA in mouse, which is vital for efficient activation of downstream profibrotic genes, contributing to the pathogenesis of liver fibrosis.
Another important finding of our study is discovery of the presence of miR-19b-3p in HSCs and the inhibitory role of miR-19b-3p in CCR2-mediated liver fibrosis. Hepatic level of miR-19b-3p was decreased in CCl 4 -treated WT mice, whereas increased in CCl 4 -treated SphK1 2/2 mice. In addition, miR-19b-3p expression was raised in SphK1-deficient HSCs compared with WT HSCs. Moreover, either SphK1 deficiency or exogenous miR-19b-3p mimic abrogated the expression of CCR2 and fibrogenic factors. Additionally, expression of fibrogenic genes was markedly induced by anti-miR-19b-3p even in activated HSCs deficient with SphK1. These data suggested that SphK1 deficiency downregulate CCR2 via upregulation of miR-19b-3p in HSCs as well as fibrotic liver.
Recent studies reported that manipulating the expression of dysregulated miRNAs showed an antifibrotic effect in mouse model of CCl 4 -induced liver fibrosis. (35, 36) Our current study also demonstrated that upregulation of miR-19b-3p by SphK1 deficiency attenuated CCl 4 -induced liver fibrosis. However, the systemic delivery of RNA-based therapeutics in vivo remains a challenge due to the presence of serum nucleases in blood, the poor uptake by the cells in the targeted tissues and rapid clearance by the renal system. (37) The newly-developed nanomedicine can minimize these negative effects. Recently, nanoparticles (NPs) made from an amino acid-based polymer have been shown to effectively transfect tissue in vivo. Rodent liver fibrosis was rescued by even a single injection of NPs having miR-378a-3p. (38) Thus, miR-19b-3p encapsulated with NPs will need to be developed as RNA delivery vehicles to validate the therapeutic roles of miR-19b-3p in the treatment of liver fibrosis.
In conclusion, our current study demonstrates that SphK1 has distinct roles in KCs and HSCs in the pathogenesis of liver injury and fibrosis. SphK1 on KCs regulates the migration of KCs and secretion of CCL2. Furthermore, SphK1 expressed in HSCs is more crucial for the pathogenesis of liver fibrosis. Our study also demonstrates that miR-19b-3p suppresses the activation of HSCs by targeting CCR2, and SphK1-deficient HSCs repress the transcriptional expression of miR-19b-3p to suppress the expression of CCR2 and the activation of HSCs, protecting against liver fibrosis. The interaction of SphK1-CCL2-CCR2 as a key molecular event in the activation of HSCs. All of these results strengthen the conclusion that activation of SphK1 signaling in HSCs and KCs indeed contributes to the development and progression of liver fibrosis (Supporting Fig. S7 ). These findings indicate that SphK1 has great potential to be used as a therapeutic agent for treating liver fibrosis.
